Do analysts recommend GALT or SCLX?

Galectin Therapeutics currently has a consensus target price of $11.00, suggesting a potential upside of 175.00%. Given Galectin Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Galectin Therapeutics is more favorable than Scilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galectin Therapeutics 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GALT or SCLX more profitable?

Galectin Therapeutics has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%. Company Net Margins Return on Equity Return on Assets Galectin Therapeutics N/A N/A -164.69% Scilex -1,110.17% N/A -143.55%

Does the media refer more to GALT or SCLX?

In the previous week, Galectin Therapeutics had 2 more articles in the media than Scilex. MarketBeat recorded 3 mentions for Galectin Therapeutics and 1 mentions for Scilex. Scilex's average media sentiment score of 0.00 beat Galectin Therapeutics' score of -0.45 indicating that Scilex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galectin Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Scilex 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate SCLX or BCYC?

Bicycle Therapeutics has a consensus price target of $14.00, indicating a potential upside of 236.54%. Given Bicycle Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Bicycle Therapeutics is more favorable than Scilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bicycle Therapeutics 1 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.44

Does the media prefer SCLX or BCYC?

In the previous week, Bicycle Therapeutics had 2 more articles in the media than Scilex. MarketBeat recorded 3 mentions for Bicycle Therapeutics and 1 mentions for Scilex. Scilex's average media sentiment score of 0.00 beat Bicycle Therapeutics' score of -0.03 indicating that Scilex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scilex 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bicycle Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend SCLX or EDIT?

Editas Medicine has a consensus target price of $5.40, indicating a potential upside of 87.50%. Given Editas Medicine's stronger consensus rating and higher probable upside, analysts plainly believe Editas Medicine is more favorable than Scilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Editas Medicine 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Which has higher valuation and earnings, SCLX or EDIT?

Editas Medicine has higher revenue and earnings than Scilex. Editas Medicine is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scilex $30.25M 2.14 -$358.73M -$40.47 N/A Editas Medicine $40.52M 6.96 -$160.06M -$1.23 N/A

Is SCLX or EDIT more profitable?

Editas Medicine has a net margin of -281.59% compared to Scilex's net margin of -1,110.17%. Scilex's return on equity of 0.00% beat Editas Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Scilex -1,110.17% N/A -143.55% Editas Medicine -281.59% -677.39% -58.25%

Does the media prefer SCLX or EDIT?

In the previous week, Scilex and Scilex both had 1 articles in the media. Editas Medicine's average media sentiment score of 1.16 beat Scilex's score of 0.00 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scilex 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Editas Medicine 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend SCLX or INDP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer SCLX or ELDN?

Eledon Pharmaceuticals has a consensus price target of $9.67, suggesting a potential upside of 150.43%. Given Eledon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Eledon Pharmaceuticals is more favorable than Scilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Eledon Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Scilex (SCLX) Competitors

$7.64 -0.80 (-9.48%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$7.50 -0.14 (-1.83%)

As of 07/20/2026 07:45 PM Eastern

Compare

SCLX vs. GALT, BCYC, EDIT, INDP, and ELDN

Should you buy Scilex stock or one of its competitors? MarketBeat compares Scilex with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Scilex include Galectin Therapeutics (GALT), Bicycle Therapeutics (BCYC), Editas Medicine (EDIT), Indaptus Therapeutics (INDP), and Eledon Pharmaceuticals (ELDN). These companies are all part of the "pharmaceutical products" industry.

How does Scilex compare to Galectin Therapeutics?

Galectin Therapeutics (NASDAQ:GALT) and Scilex (NASDAQ:SCLX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

Galectin Therapeutics has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%.

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-164.69%
Scilex	-1,110.17%	N/A	-143.55%

Galectin Therapeutics has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, Scilex has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market.

11.7% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 69.7% of Scilex shares are owned by institutional investors. 52.6% of Galectin Therapeutics shares are owned by insiders. Comparatively, 4.5% of Scilex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Galectin Therapeutics has higher earnings, but lower revenue than Scilex. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.41	N/A
Scilex	$30.25M	2.14	-$358.73M	-$40.47	N/A

Galectin Therapeutics currently has a consensus target price of $11.00, suggesting a potential upside of 175.00%. Given Galectin Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Galectin Therapeutics is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Galectin Therapeutics had 2 more articles in the media than Scilex. MarketBeat recorded 3 mentions for Galectin Therapeutics and 1 mentions for Scilex. Scilex's average media sentiment score of 0.00 beat Galectin Therapeutics' score of -0.45 indicating that Scilex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galectin Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Scilex	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Galectin Therapeutics beats Scilex on 8 of the 14 factors compared between the two stocks.

How does Scilex compare to Bicycle Therapeutics?

Scilex (NASDAQ:SCLX) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Bicycle Therapeutics has higher revenue and earnings than Scilex. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scilex	$30.25M	2.14	-$358.73M	-$40.47	N/A
Bicycle Therapeutics	$72.86M	3.99	-$218.96M	-$3.15	N/A

Bicycle Therapeutics has a net margin of -344.95% compared to Scilex's net margin of -1,110.17%. Scilex's return on equity of 0.00% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scilex	-1,110.17%	N/A	-143.55%
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%

Bicycle Therapeutics has a consensus price target of $14.00, indicating a potential upside of 236.54%. Given Bicycle Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Bicycle Therapeutics is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

69.7% of Scilex shares are owned by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are owned by institutional investors. 4.5% of Scilex shares are owned by insiders. Comparatively, 22.0% of Bicycle Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Bicycle Therapeutics had 2 more articles in the media than Scilex. MarketBeat recorded 3 mentions for Bicycle Therapeutics and 1 mentions for Scilex. Scilex's average media sentiment score of 0.00 beat Bicycle Therapeutics' score of -0.03 indicating that Scilex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scilex	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bicycle Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Scilex has a beta of 1.66, indicating that its share price is 66% more volatile than the broader market. Comparatively, Bicycle Therapeutics has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market.

Summary

Bicycle Therapeutics beats Scilex on 12 of the 16 factors compared between the two stocks.

How does Scilex compare to Editas Medicine?

Scilex (NASDAQ:SCLX) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

Editas Medicine has a net margin of -281.59% compared to Scilex's net margin of -1,110.17%. Scilex's return on equity of 0.00% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scilex	-1,110.17%	N/A	-143.55%
Editas Medicine	-281.59%	-677.39%	-58.25%

Editas Medicine has a consensus target price of $5.40, indicating a potential upside of 87.50%. Given Editas Medicine's stronger consensus rating and higher probable upside, analysts plainly believe Editas Medicine is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Scilex has a beta of 1.66, meaning that its share price is 66% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.1, meaning that its share price is 110% more volatile than the broader market.

69.7% of Scilex shares are held by institutional investors. Comparatively, 71.9% of Editas Medicine shares are held by institutional investors. 4.5% of Scilex shares are held by company insiders. Comparatively, 3.1% of Editas Medicine shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Scilex and Scilex both had 1 articles in the media. Editas Medicine's average media sentiment score of 1.16 beat Scilex's score of 0.00 indicating that Editas Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scilex	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Editas Medicine	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Editas Medicine has higher revenue and earnings than Scilex. Editas Medicine is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scilex	$30.25M	2.14	-$358.73M	-$40.47	N/A
Editas Medicine	$40.52M	6.96	-$160.06M	-$1.23	N/A

Summary

Editas Medicine beats Scilex on 12 of the 15 factors compared between the two stocks.

How does Scilex compare to Indaptus Therapeutics?

Scilex (NASDAQ:SCLX) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability.

Indaptus Therapeutics has lower revenue, but higher earnings than Scilex. Scilex is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scilex	$30.25M	2.14	-$358.73M	-$40.47	N/A
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A

69.7% of Scilex shares are owned by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are owned by institutional investors. 4.5% of Scilex shares are owned by company insiders. Comparatively, 9.9% of Indaptus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Indaptus Therapeutics has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%. Scilex's return on equity of 0.00% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scilex	-1,110.17%	N/A	-143.55%
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%

In the previous week, Scilex had 1 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 1 mentions for Scilex and 0 mentions for Indaptus Therapeutics. Scilex's average media sentiment score of 0.00 equaled Indaptus Therapeutics'average media sentiment score.

Company	Overall Sentiment
Scilex	Neutral
Indaptus Therapeutics	Neutral

Scilex has a beta of 1.66, suggesting that its share price is 66% more volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Scilex beats Indaptus Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Scilex compare to Eledon Pharmaceuticals?

Scilex (NASDAQ:SCLX) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Eledon Pharmaceuticals has lower revenue, but higher earnings than Scilex. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scilex	$30.25M	2.14	-$358.73M	-$40.47	N/A
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A

Scilex has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market. Comparatively, Eledon Pharmaceuticals has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market.

Eledon Pharmaceuticals has a consensus price target of $9.67, suggesting a potential upside of 150.43%. Given Eledon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Eledon Pharmaceuticals is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

69.7% of Scilex shares are held by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 4.5% of Scilex shares are held by company insiders. Comparatively, 9.6% of Eledon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Eledon Pharmaceuticals has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%. Scilex's return on equity of 0.00% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scilex	-1,110.17%	N/A	-143.55%
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%

In the previous week, Scilex had 1 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 1 mentions for Scilex and 0 mentions for Eledon Pharmaceuticals. Scilex's average media sentiment score of 0.00 equaled Eledon Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Scilex	Neutral
Eledon Pharmaceuticals	Neutral

Summary

Eledon Pharmaceuticals beats Scilex on 8 of the 14 factors compared between the two stocks.

Get Scilex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SCLX vs. The Competition

Export

Metric	Scilex	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$71.67M	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-0.19	20.49	27.10	23.94
Price / Sales	2.14	300.39	517.51	91.94
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	-0.31	7.92	10.66	6.14
Net Income	-$358.73M	$23.81M	$3.60B	$331.74M
7 Day Performance	-12.79%	-1.09%	-1.23%	-1.81%
1 Month Performance	2.28%	2.56%	1.11%	-1.44%
1 Year Performance	-11.16%	42.16%	23.65%	16.33%

Scilex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SCLX Scilex	0.5204 of 5 stars	$7.64 -9.5%	N/A	-13.8%	$71.67M	$30.25M	N/A	80
GALT Galectin Therapeutics	1.7432 of 5 stars	$4.72 +2.6%	$11.00 +133.1%	+42.9%	$310.86M	N/A	N/A	9
BCYC Bicycle Therapeutics	2.4748 of 5 stars	$4.33 -0.4%	$14.00 +223.0%	-51.4%	$308.14M	$72.86M	N/A	240
EDIT Editas Medicine	2.8084 of 5 stars	$3.09 -2.2%	$5.40 +74.7%	+4.3%	$302.54M	$40.52M	N/A	230	Gap Down
INDP Indaptus Therapeutics	0.5086 of 5 stars	$2.61 -0.8%	N/A	-78.8%	$298.39M	N/A	N/A	6

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SCLX) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Scilex (SCLX) Competitors

SCLX vs. GALT, BCYC, EDIT, INDP, and ELDN

How does Scilex compare to Galectin Therapeutics?

Summary

How does Scilex compare to Bicycle Therapeutics?

Summary

How does Scilex compare to Editas Medicine?

Summary

How does Scilex compare to Indaptus Therapeutics?

Summary

How does Scilex compare to Eledon Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCLX vs. The Competition

Scilex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Scilex (SCLX) Competitors

SCLX vs. GALT, BCYC, EDIT, INDP, and ELDN

How does Scilex compare to Galectin Therapeutics?

Is GALT or SCLX more profitable?

Which has more risk and volatility, GALT or SCLX?

Do insiders and institutionals have more ownership in GALT or SCLX?

Which has higher valuation and earnings, GALT or SCLX?

Do analysts recommend GALT or SCLX?

Does the media refer more to GALT or SCLX?

Summary

How does Scilex compare to Bicycle Therapeutics?

Which has higher earnings and valuation, SCLX or BCYC?

Is SCLX or BCYC more profitable?

Do analysts rate SCLX or BCYC?

Do insiders and institutionals believe in SCLX or BCYC?

Does the media prefer SCLX or BCYC?

Which has more volatility and risk, SCLX or BCYC?

Summary

How does Scilex compare to Editas Medicine?

Is SCLX or EDIT more profitable?

Do analysts recommend SCLX or EDIT?

Which has more volatility and risk, SCLX or EDIT?

Do insiders and institutionals hold more shares of SCLX or EDIT?

Does the media prefer SCLX or EDIT?

Which has higher valuation and earnings, SCLX or EDIT?

Summary

How does Scilex compare to Indaptus Therapeutics?

Which has higher earnings and valuation, SCLX or INDP?

Do institutionals & insiders believe in SCLX or INDP?

Is SCLX or INDP more profitable?

Does the media prefer SCLX or INDP?

Which has more risk and volatility, SCLX or INDP?

Do analysts recommend SCLX or INDP?

Summary

How does Scilex compare to Eledon Pharmaceuticals?

Which has preferable earnings and valuation, SCLX or ELDN?

Which has more risk and volatility, SCLX or ELDN?

Do analysts prefer SCLX or ELDN?

Do insiders & institutionals have more ownership in SCLX or ELDN?

Is SCLX or ELDN more profitable?

Does the media refer more to SCLX or ELDN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCLX vs. The Competition

Scilex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools